Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

Phase 1 Completed 24 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multiple dose study of NSA-789, the purpose of which is to assess the safety and tolerability in healthy subjects and subjects with Alzheimer's Disease

Timeline

Start: 2009-01
Primary completion: 2009-05
Completion: 2009-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NSA-789	Unknown	—	Oral

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789

Summary

Timeline

Drugs

Indications